Domingo P, Sambeat MA, Arroyo JA, Fontanet A, Ordonez J, Cadafalch J, Fuster M, Orellana I, Gurgui M, Vazquez G; International Conference on AIDS.

Int Conf AIDS. 2002 Jul 7-12; 14: abstract no. TuPeB4536.

Hospital de St. Pau, Barcelona, Spain

BACKGROUND: Combination antiretroviral therapy is known to induce disturbances of lipid metabolism Aim of the study: to compare the lipid profile of patients randomized to receive either indinavir or nevirapine together with didanosine and stavudine Patients and methods: HIV-infected, antiretroviral naive patients were randomized to receive either IDV or NVP each of them combined with stavudine and didanosine. Serum total cholesterol and triglycerides (TG) were measured by fully enzymatic standard method and HDL by a direct method using polyethylene glycol modified enzymes. LDL was measured after ultracentrifugation utilising the PEGME method for HDL cholesterol instead of precipitation. VLDL was measured in the fraction of d< 1006 kg/l of the ultracentrifugation. Statistical analyses were performed with the StatViewTM 4.5 statistical package. RESULTS: One hundred and two patients were included in the study. There were 81 men and 21 women with a mean age of 39.3 +/- 9.9 years (range: 18-66). Thirty five patients had a stage C3 HIV infection. Forty-seven were assigned to IDV and 55 to NVP. There were not statistically significant differences between groups at baseline with respect to CD4 count, viral load, total cholesterol, triglycerides, HDL, LDL, and VLDL cholesterol. TG values were significantly higher at 3 and 12 months with respect to baseline (p < 0.05) in the IDV group, whereas for NVP there were no statistically significant differences at any time point. Cholesterol values were significantly higher at 3, 6, 9, and 12 months with respect to baseline (p < 0.05) in the IDV group, and the same occurred in the NVP group (p < 0.05). There were no significant changes in the HDL cholesterol levels in the IDV group, whereas it showed a significant increase in the NVP group (p = 0.04). CONCLUSIONS: Combination antiretroviral therapy that includes NVP induces a less harmful lipid profile that regimes that include IDV.

Publication Types:

• Meeting Abstracts

Keywords:

• AIDS Vaccines
• Acquired Immunodeficiency Syndrome
• CD4 Lymphocyte Count
• Clinical Trials as Topic
• Didanosine
• Female
• HIV Infections
• HIV Seropositivity
• Humans
• Indinavir
• Lipids
• Male
• Nevirapine
• Stavudine
• Viral Load

Other ID:

• GWAIDS0020604

UI: 102259670

From Meeting Abstracts